Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing medicines targeting diseases driven by dysregulated aldosterone. Its lead product, lorundrostat, is a highly selective oral aldosterone synthase inhibitor aimed at treating hypertension, chronic kidney disease, and obstructive sleep apnea. The company focuses on innovative therapies for cardiorenal conditions, leveraging proprietary compounds and strategic licensing to address unmet medical needs in cardiovascular and renal health.
This description was generated via AI from an annual report. Updated about 1 year ago.